Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice

被引:1
作者
Prajeeth, Chittappen K. [1 ]
Zdora, Isabel [2 ]
Saletti, Giulietta [1 ]
Friese, Julia [1 ]
Gerlach, Thomas [1 ]
Wilken, Lucas [1 ,3 ]
Beicht, Jana [1 ]
Kubinski, Mareike [1 ]
Puff, Christina [2 ]
Baumgaertner, Wolfgang [2 ]
Kortekaas, Jeroen [4 ,5 ]
Schreur, Paul J. Wichgers [4 ,6 ]
Osterhaus, Albert D. M. E. [1 ]
Rimmelzwaan, Guus F. [1 ]
机构
[1] Univ Vet Med Hannover, Res Ctr Emerging Infect & Zoonoses, Hannover, Germany
[2] Univ Vet Med Hannover, Dept Pathol, Hannover, Germany
[3] Leibniz Inst Virol LIV, Hamburg, Germany
[4] Wageningen Univ & Res, Wageningen Biovet Res, Lelystad, Netherlands
[5] Boehringer Ingelheim Anim Hlth, St Priest, France
[6] BnyaVax BV, Radiobiol, Lelystad, Netherlands
关键词
RVFV; immunogenicity; T cells; antibodies; vaccines; EFFICACY; ANTIBODY; SAFETY;
D O I
10.1080/22221751.2024.2373313
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rift Valley fever (RVF) is a mosquito-borne zoonotic disease caused by RVF virus (RVFV). RVFV infections in humans are usually asymptomatic or associated with mild febrile illness, although more severe cases of haemorrhagic disease and encephalitis with high mortality also occur. Currently, there are no licensed human vaccines available. The safety and efficacy of a genetically engineered four-segmented RVFV variant (hRVFV-4s) as a potential live-attenuated human vaccine has been tested successfully in mice, ruminants, and marmosets though the correlates of protection of this vaccine are still largely unknown. In the present study, we have assessed hRVFV-4s-induced humoral and cellular immunity in a mouse model of RVFV infection. Our results confirm that a single dose of hRVFV-4s is highly efficient in protecting na & iuml;ve mice from developing severe disease following intraperitoneal challenge with a highly virulent RVFV strain and data show that virus neutralizing (VN) serum antibody titres in a prime-boost regimen are significantly higher compared to the single dose. Subsequently, VN antibodies from prime-boost-vaccinated recipients were shown to be protective when transferred to na & iuml;ve mice. In addition, hRVFV-4s vaccination induced a significant virus-specific T cell response as shown by IFN-gamma ELISpot assay, though these T cells did not provide significant protection upon passive transfer to na & iuml;ve recipient mice. Collectively, this study highlights hRVFV-4s-induced VN antibodies as a major correlate of protection against lethal RVFV infection.
引用
收藏
页数:10
相关论文
共 30 条
[1]   Identification and Characterization of Rift Valley Fever Virus-Specific T Cells Reveals a Dependence on CD40/CD40L Interactions for Prevention of Encephalitis [J].
Barbeau, Dominique J. ;
Cartwright, Haley N. ;
Harmon, Jessica R. ;
Spengler, Jessica R. ;
Spiropoulou, Christina F. ;
Sidney, John ;
Sette, Alessandro ;
McElroy, Anita K. .
JOURNAL OF VIROLOGY, 2021, 95 (23)
[2]  
Bian T, 2023, NPJ VACCINES, V8, DOI [10.1038/s41541-023-00763-2, 10.1038/s41541-023-00780-1]
[3]   Single-dose of a replication-competent adenovirus-vectored vaccine provides sterilizing protection against Rift Valley fever virus challenge [J].
Bian, Ting ;
Wang, Busen ;
Fu, Guangcheng ;
Hao, Meng ;
Chen, Yi ;
Fang, Ting ;
Liu, Shuling ;
Yu, Changming ;
Li, Jianmin ;
Chen, Wei .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[4]  
Bron GM., 2023, Front Cell Infect Mi, V13
[5]   Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses [J].
Chapman, Nathaniel S. ;
Hulswit, Ruben J. G. ;
Westover, Jonna L. B. ;
Stass, Robert ;
Paesen, Guido C. ;
Binshtein, Elad ;
Reidy, Joseph X. ;
Engdahl, Taylor B. ;
Handal, Laura S. ;
Flores, Alejandra ;
Gowen, Brian B. ;
Bowden, Thomas A. ;
Crowe, James E., Jr. .
NATURE COMMUNICATIONS, 2023, 14 (01)
[6]  
Dodd KA., 2014, Plos Neglect Trop D, V8
[7]   Rift Valley Fever Virus Clearance and Protection from Neurologic Disease Are Dependent on CD4+ T Cell and Virus-Specific Antibody Responses [J].
Dodd, Kimberly A. ;
McElroy, Anita K. ;
Jones, Megan E. B. ;
Nichol, Stuart T. ;
Spiropoulou, Christina F. .
JOURNAL OF VIROLOGY, 2013, 87 (11) :6161-6171
[8]   Immune correlates of protection following Rift Valley fever virus vaccination [J].
Doyle, Joshua D. ;
Barbeau, Dominique J. ;
Cartwright, Haley N. ;
McElroy, Anita K. .
NPJ VACCINES, 2022, 7 (01)
[9]   Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, Dengue virus, and Yellow fever virus by real-time reverse transcription-PCR [J].
Drosten, C ;
Göttig, S ;
Schilling, S ;
Asper, M ;
Panning, M ;
Schmitz, H ;
Günther, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (07) :2323-2330
[10]   Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep [J].
Dungu, Baptiste ;
Louw, Ian ;
Lubisi, Alison ;
Hunter, Pamela ;
von Teichman, Beate F. ;
Bouloy, Michele .
VACCINE, 2010, 28 (29) :4581-4587